Companies › Vironexis Biotherapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VNX-101 Adeno-associated viral vector encoding CD3/CD19 bi-specific T-cell engager | CD3, CD19 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Jun 2027 |
| VNX-202 Adeno-associated viral vector encoding CD3/HER2 bi-specific T-cell engager | CD3, ERBB2 | Phase 1 | HER2 Expressing Solid Tumors | Sep 2033 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06533579 | VNX-101 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Oncology | Jun 2027 |
| NCT07192432 | VNX-202 | Phase 1 | HER2 Expressing Solid Tumors | Oncology | Sep 2033 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.